Clinical trial
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
NCT00419328 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00419328 |
|---|---|
| Title | A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors |
| Official title | NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | NGR-hTNF |
| Enrollment | 16 |
| Start date | Mar 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Jan 8, 2007 |
| Last update posted | Jul 21, 2022 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: